Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPA-ESUS: Empagliflozin for Left Atrial Function in ESUS
NCT06715449Phase 3Recruiting
- Sponsor
- University of East Anglia
- Start
- Nov 2024
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of empagliflozin in Atrial fibrillation (AFib) (2 arms), sponsored by University of East Anglia. Primary endpoint: Change in left atrial reservoir strain at 6 months. Started Nov 2024; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT06715449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06715449.